Business Context and Reporting Period
This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly and six-month periods ended June 30, 2002. The company is a global pharmaceutical and consumer health products manufacturer. The filing highlights significant operational challenges, including a consent decree with the FDA regarding manufacturing practices and ongoing patent litigation surrounding its key product, CLARITIN.
Key Financial Metrics
| Metric | Q2 2002 | Q2 2001 | 6 Months 2002 | 6 Months 2001 |
|---|---|---|---|---|
| Net Sales | $2,833 million | $2,618 million | $5,389 million | $4,924 million |
| Net Income | $633 million | $634 million | $1,232 million | $1,198 million |
| Diluted EPS | $0.43 | $0.43 | $0.84 | $0.81 |
| Operating Cash Flow (6mo) | $870 million (vs. $1,051 million in 2001) | |||
| Cash and Equivalents | $3,160 million (as of June 30, 2002) | |||
| Short-term Debt | $911 million (as of June 30, 2002) | |||
| Cost of Sales Margin | 23.8% | 20.4% | 23.3% | 20.4% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 8% in Q2 and 9% year-to-date. International sales drove growth (up 21% in Q2), while U.S. sales grew only 1%.
- Product Performance:
- Anti-infective & Anticancer: Sales surged 75% in Q2, led by the INTRON franchise (up 90% YTD) and TEMODAR.
- Allergy & Respiratory: Sales declined 8% in Q2. CLARITIN family sales dropped 14% due to patient conversion to CLARINEX and market share losses.
- Cardiovasculars: Sales fell 14% in Q2, primarily due to a 73% decline in K-DUR from generic competition.
- Profitability: Net income remained flat in Q2 ($633M vs $634M) despite revenue growth. Income before taxes as a percentage of sales decreased from 31.4% to 29.0% due to higher cost of sales and increased R&D spending.
- Cash Flow: Operating cash flow decreased by $181 million year-to-date, largely attributed to the $250 million payment made in May 2002 under the FDA consent decree.
Guidance, Outlook, Risks, and Unusual Items
Consent Decree and Manufacturing Issues
Schering-Plough reached a consent decree with the FDA to resolve Good Manufacturing Practices (GMP) violations at facilities in New Jersey and Puerto Rico. The company agreed to pay $500 million to the U.S. government (first installment paid in May 2002). Failure to meet revalidation deadlines could result in additional daily fines and a 24.6% royalty on net U.S. sales for affected products. Production of certain animal health products (BANAMINE, NUFLOR) was temporarily suspended.
CLARITIN Patent Litigation and OTC Switch
A federal court ruled in August 2002 that certain claims of a patent protecting CLARITIN (expiring 2004) were invalid. The company is appealing. Generic loratadine could enter the market as early as December 20, 2002. Management warns that generic entry or an Over-the-Counter (OTC) switch could cause a "rapid, sharp and material decline" in sales. The company expects the elimination of trade inventory for prescription CLARITIN upon OTC approval to negatively impact pretax profits by approximately $250 million for the remainder of 2002.
Legal and Regulatory Risks
- AWP Investigations: Multiple state and federal investigations are ongoing regarding the reporting of Average Wholesale Prices (AWP), with potential for fines and penalties.
- Antitrust: The FTC is appealing a decision dismissing claims regarding anti-competitive patent settlements for K-DUR.
- Securities Litigation: A consolidated shareholder class action regarding the disclosure of FDA manufacturing issues remains pending.
Capital Allocation
The company increased its quarterly dividend to $0.17 per share. Capital expenditures for the first six months were $321 million, with full-year expectations exceeding $775 million. The share repurchase program (authorized at $1.5 billion) was suspended in 2001 and remains inactive.
Investor Verification Checklist
- CLARITIN Patent Appeal: Monitor the status of the appeal regarding the August 2002 court ruling invalidating the 2004 patent; a loss could accelerate generic competition.
- Consent Decree Compliance: Verify the company's progress on revalidation plans to avoid the 24.6% royalty penalty and additional fines.
- OTC Switch Timing: Track the FDA's decision on the OTC switch for CLARITIN, which is expected to trigger a $250 million hit to pretax profits in late 2002.
- AWP Litigation Outcomes: Review developments in the coordinated federal court cases regarding Average Wholesale Price reporting, which could result in significant financial penalties.
- PEG-INTRON Supply: Confirm that the "Access Assurance" program is effectively managing demand for PEG-INTRON to prevent revenue loss from supply constraints.